P2Y12 Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting

Publication Date

2014

Journal Title

J Card Surg

Abstract

Background The use of platelet function testing has been advocated to individualize the time needed between discontinuation of P2Y12 inhibitors and coronary artery bypass grafting (CABG). However, the use of specific point-of-care assays to predict bleeding risk in patients on P2Y12 inhibitors prior to CABG has not been fully validated. Methods From September 2012 to May 2013, 81 patients on P2Y12 inhibitors underwent isolated CABG. Preoperative level of P2Y12 receptor blockade was measured using the VerifyNow P2Y12 assay. Packed red blood cell (pRBC) and platelet transfusions and postoperative chest tube output were correlated with preoperative P2Y12 reaction units (PRUs). Results Patients who stopped P2Y12 inhibitors for

Volume Number

29

Issue Number

3

Pages

312-316

Document Type

Article

EPub Date

2014/03/05

Status

Faculty, Northwell Researcher

Facility

School of Medicine; Northwell Health

Primary Department

Cardiovascular and Thoracic Surgery

Additional Departments

General Internal Medicine

PMID

24588751

DOI

10.1111/jocs.12312

For the public and Northwell Health campuses

Share

COinS